Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Milestone Pharmaceuticals (Nasdaq: MIST) granted a total of 30,000 stock options as inducement awards to two newly hired employees under its 2021 Inducement Plan, with a grant date of December 1, 2025.
The options have an exercise price of $2.69 per share (equal to the closing price on the grant date) and vest over four years: 25% at the one-year anniversary and the remainder in 36 equal monthly installments. Awards are subject to continuous service and standard plan terms and were made in accordance with Nasdaq Listing Rule 5635(c)(4).
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, MIST declined 1.49%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
MIST was up 1.52% while close peers were mixed: ACOG -2.83%, VTYX -1.16% (with separate news and a -15.35% reaction), CYBN +4.83%, GLSI +10.93%, KYTX +3.21%, suggesting stock-specific dynamics rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 02 | Inducement grants | Neutral | -1.5% | 30,000 stock options granted as inducement awards to two new hires. |
| Nov 12 | Earnings and update | Positive | +1.1% | Q3 2025 results, cash of $82.6M and PDUFA date for CARDAMYST. |
| Nov 04 | Inducement grants | Neutral | -2.2% | 65,000 stock options granted under 2021 Inducement Plan for new hires. |
| Nov 03 | Clinical data update | Positive | -3.6% | Pooled etripamil PSVT data showing consistent efficacy and safety across trials. |
| Oct 09 | Conference presentation | Neutral | +4.5% | Announcement of upcoming AHA 2025 poster on etripamil efficacy and safety. |
Recent inducement grant announcements have been neutral in tone and followed by modest single-digit percentage price moves, while clinical data news has occasionally seen negative price reactions despite positive efficacy and safety descriptions.
Over the last few months, Milestone has combined routine HR-related inducement grants with significant clinical and regulatory progress. Inducement option grants on Nov 3, 2025 and Dec 1, 2025 produced small single-day moves of -2.17% and -1.49%, respectively. In contrast, a Q3 2025 update on Nov 12, 2025 highlighted $82.6 million in cash and an upcoming Dec 13, 2025 PDUFA date. Pooled etripamil data presented around AHA Sessions, with 622 patients and favorable efficacy, drew a -3.65% move on Nov 3, 2025, while an earlier conference poster announcement on Oct 9, 2025 coincided with a +4.5% reaction.
Market Pulse Summary
This announcement details a routine HR-related equity grant: 30,000 stock options at a $2.69 exercise price, vesting over 4 years under Nasdaq Listing Rule 5635(c)(4). It follows earlier inducement grants and sits against a backdrop of sizeable net losses but cash of $82.6 million and senior secured convertible notes of $56.2 million as of September 30, 2025. Investors tracking dilution and governance may watch future equity compensation levels and how they interact with ongoing regulatory and clinical milestones.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. Not financial advice.
MONTREAL and CHARLOTTE, N.C., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a total of 30,000 options (the “Options”) to purchase the Company’s common shares, pursuant to the Company’s 2021 Inducement Plan (the “Plan”), previously approved by the Company’s Compensation Committee and the Board of Directors, as a material inducement to the hiring of two new employees.
The Options have a grant date of December 1, 2025, and an exercise price of
The Option awards are subject to the award holder’s continuous service through each vesting date and to the terms and conditions of the Plan and its standard forms of grant agreements thereunder.
The foregoing equity award was granted as an inducement material to the employee entering into employment with Milestone, in accordance with Nasdaq Listing Rule 5635(c)(4). The Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Milestone, or following a bona fide period of non-employment, as an inducement material to such individual’s entering into employment with Milestone, pursuant to Nasdaq Listing Rule 5635(c)(4).
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company’s focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat symptomatic episodic attacks associated with PSVT and AFib-RVR.
Contact:
Kevin Gardner kgardner@lifesciadvisors.com
FAQ
What did Milestone Pharmaceuticals (MIST) announce on December 2, 2025?
What is the exercise price of the MIST inducement options granted Dec 1, 2025?
How do the MIST options granted under the 2021 Inducement Plan vest?
Why did Milestone use the 2021 Inducement Plan for the MIST options?
How many employees received inducement options from Milestone (MIST)?
Are the MIST option awards conditional on continued employment?
